Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Deaths reported in Lebanon as Israel and Hezbollah exchange attacks - 2Was it a stone tool or just a rock? An archaeologist explains how scientists can tell the difference
- 3‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support
- 45 Cell phones of the Year
- 5Linda Hamilton, 69, says she doesn't want to 'chase longevity'
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- The Best Games Crossroads in History
- Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
- Astronomers spot white dwarf star creating a colorful shockwave
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- India’s delayed climate plan sets modest emission target
- Record-breaking flu hospitalizations in New York in a single week: Health officials
- France's Senate backs ban on social media platforms for under-15s
- The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
